SAN DIEGO--(BUSINESS WIRE)--March 7, 2006--Illumina, Inc. (NASDAQ:ILMN) announced today the commercial availability of three new GoldenGate(R) single nucleotide polymorphism (SNP) assay panels designed to study genetic variation and help researchers understand how certain genotypes impact disease. Illumina has also introduced a 96-plex Sentrix(R) universal array, further expanding the multiplexing flexibility of custom GoldenGate genotyping. Supplementing the catalog offerings is a new test panel to screen DNA samples for predictive assay quality.
